Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

J.P. Morgan Reaffirms Their Sell Rating on Fresenius Medical Care AG & Co. KGaA (0H9X)

Tipranks - Tipranks - Sat Mar 14, 7:14AM CDT

In a report released today, David Adlington from J.P. Morgan maintained a Sell rating on Fresenius Medical Care AG & Co. KGaA, with a price target of €37.40.

Claim 70% Off TipRanks Premium

According to TipRanks, Adlington is an analyst with an average return of -6.1% and a 39.84% success rate. Adlington covers the Healthcare sector, focusing on stocks such as Fresenius SE & Co. KGaA, Fresenius Medical Care AG & Co. KGaA, and Siemens Healthineers AG.

In addition to J.P. Morgan, Fresenius Medical Care AG & Co. KGaA also received a Sell from UBS’s Graham Doyle in a report issued on March 10. However, yesterday, Barclays maintained a Hold rating on Fresenius Medical Care AG & Co. KGaA (LSE: 0H9X).

See the top stocks recommended by analysts >>

0H9X market cap is currently €11.56B and has a P/E ratio of 12.14.

Read More on GB:0H9X:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).